Mouse mammary tumor virus (MMTV) is an insertional mutagen that has been demonstrated to transcriptionally activate¯anking cellular proto-oncogenes. Previously we have used MMTV infection to accelerate mammary tumorigenesis in Wnt1 transgenic mice in order to identify genes that cooperate with the Wnt1 oncogene. Initial investigations into the resulting tumor collection, screened primarily by Southern analysis, showed that three ®broblast growth factor genes, Fgf8, Fgf3 and Fgf4, sustain activating insertion mutations in 10%, 42% and 6% of the tumors, respectively. Here, in an examination of the tumors from MMTV-infected Wnt1 transgenic mice that emphasizes Northern analysis, we report transcriptional activation of Fgf8 in 30 additional tumors (increasing the percentage of activations to 50%), while no signi®cant changes in the activation frequency of Fgf3 or Fgf4 were found. To determine the frequency of insertional activation in normal mice, we examined tumors from MMTV-infected nontransgenic littermates of the Wnt1 transgenics and from MMTVinfected BALB/c mice. Fgf8, Fgf3 and Fgf4 were found to be activated in 11%, 80% and 5%, respectively, of the tumors in the combined nontransgenic groups. Thus, there appears to be an increased predisposition for Fgf8 activations in Wnt1 transgenic mice versus normal mice, suggesting that cells expressing Wnt1 are especially sensitized to stimulation by FGF8 compared with FGF3 or FGF4. In contrast, the activation frequency of Fgf3 in tumors from MMTV-infected Wnt1 transgenic mice was approximately one-half that of normal mice. Our results show that this in vivo model of multistep tumorigenesis reveals signi®cant dierences in the activation rates of Fgf3 and Fgf8 depending upon the status of Wnt1 expression in the mammary gland. The dierential activation of these Fgfs may relate to dierences in their signaling pathways.
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Keywords: Fgf8; Wnt1; MMTV; oncogene cooperation; Fgf3; Fgf4; multistep tumorigenesis; growth factors Cancer is a multistep process that arises from the accumulation of genetic lesions over time. Therefore, to understand the development and progression of cancer, it is important to identify not only the single mutations involved, but also which oncogenes work together in tumor formation. Here, we report the results of a continuing investigation aimed at identifying and characterizing genes that cooperate with the Wnt1 oncogene in murine mammary tumorigenesis.
Wnt1 is frequently activated by proviral insertion in tumors induced by mouse mammary tumor virus (MMTV) (Nusse and Varmus, 1982) . The oncogenic potential of Wnt1 was demonstrated in vivo by ectopically expressing a Wnt1 transgene in mouse mammary glands using the MMTV enhancer (Tsukamoto et al., 1988) . Male and female Wnt1 transgenic mice develop hyperplastic mammary glands which often produce isolated carcinomas especially in breeding females. However, Wnt1 is not sucient for induction of mammary neoplasias, since tumor development occurs stochastically in these mice, and some transgenic animals remain tumor-free. Thus, additional events must be necessary for tumor induction in these animals.
To identify genes involved in these additional events, we previously infected the Wnt1 transgenic mice with MMTV (Shackleford et al., 1993) . Infection accelerated the rate of tumor formation and increased the average number of tumors per mouse, demonstrating that MMTV infection promotes mammary carcinogenesis in Wnt1 transgenics. Analysis of the tumors from these infected mice for known genetic targets of MMTV revealed insertional activation of Fgf3 and Fgf4, suggesting that these genes cooperate with Wnt1 in mammary tumorigenesis. Further examination of these tumors by cloning of integration sites and Southern blot screening identi®ed a third ®broblast growth factor gene, Fgf8, that is insertionally activated in 10% of the tumors (MacArthur et al., 1995) . This was the ®rst report of MMTV activation of the Fgf8 gene; however, no studies have been reported that test whether Fgf8 is a target for MMTV insertional mutagenesis in normal (nontransgenic) mice. Since Wnt1 is normally not expressed in the mouse mammary gland, an analysis of Fgf8 activation frequencies in tumors of normal and Wnt1 transgenic mice has the potential to reveal whether the Wnt1 signal aects the mammary gland's sensitivity to FGF8. This is an important question considering the apparent roles of Wnts and FGFs as collaborators in both normal development as well as in tumorigenesis (Peters et al., 1986; Christian et al., 1992; Kwan et al., 1992; Shackleford et al., 1993; Crossley and Martin, 1995; Lee et al., 1995; MacArthur et al., 1995; Parr and McMahon, 1995; Yang and Niswander, 1995; Crossley et al., 1996) .
In the current study, we sought to continue our investigation of the collaboration between Fgf8 and Wnt1. Our ®rst aim was to further analyse the mammary tumor panel generated from MMTV infection of Wnt1 transgenic mice by extensively testing for transcriptional activation of Fgf8 using Northern analyses. Secondly, we set out to test whether the Fgf8 gene is insertionally activated in normal mice by the same method. Additionally, we examined both tumor groups (transgenic and normal) for activation of two previously identi®ed MMTV-activated genes, Fgf3 and Fgf4, to enable a comparison with any dierences observed in Fgf8 activation between these groups.
Activation of Fgf8, Fgf3 and Fgf4 in mammary tumors from MMTV-infected Wnt1 transgenic mice Northern and Southern analyses (Figures 1a, 2 and 3) were performed in order to test for insertionally activated expression of Fgf8, Fgf3 and Fgf4 in approximately 70 mammary tumors derived from Wnt1 transgenic animals that were infected with MMTV. Northern analyses were emphasized in this study to enable detection of gene activations that might not be observed using standard Southern blotting due to the limitations of this technique ± for example, in detecting distant insertions. It is widely believed that MMTV insertions activate these Fgf genes from the transcriptionally silent state, since expression is generally not observed by Northern analysis in normal mouse mammary glands or in tumors that lack proviruses anking the gene in question (Dickson et al., 1984; Peters et al., 1989a; Shackleford et al., 1993; MacArthur et al., 1995;  Figure 1 ; data not shown). We found activation of Fgf8 in 50% (38/76), Fgf3 in 44% (28/64) and Fgf4 in 7% (4/60) of the tumors (Figures 1a and 3) . Interestingly, Fgf8 was activated in these mice at least as frequently as Fgf3, a common insertion site for MMTV in nontransgenic mice (Peters, 1990) . This indicates that Fgf8 is a stronger oncogenic collaborator with Wnt1 than previously suggested (MacArthur et al., 1995) .
Using Northern blot analysis 30 new Fgf8 activations have been found since the initial Southern blot screening of the tumor panel (MacArthur et al., 1995) . However, proviral insertions were not detected in 27 of these 30 tumors in a *36 kb region containing the Fgf8 gene, suggesting that they may have sustained insertions outside of this region ( Figure  2 and data not shown). We mapped the insertions in four of the 27 tumors to within *2.7 cM of the Fgf8 gene in the distal region of mouse chromosome 19 using interspeci®c backcross and Southern analysis (Rowe et al., 1994) . A ®fth MMTV insertion was also mapped to this chromosomal region, but RNA was not available to test for activation of Fgf8 in this tumor. It is likely that Fgf8 expression in the other 23 tumors with unmapped Fgf8 activations is also induced by long range insertional activation by MMTV. We cannot rule out that expression of Fgf8 in these cases is an indirect result of MMTV integration near or within a dierent gene whose product in turn regulates Fgf8. However, since long distance activations, apparently direct in nature, by proviral insertions are not uncommon for MMTV and other viruses, the direct scenario seems more likely (Bartholomew et al., 1989; Peters et al., 1989b; Lazo et al., 1990; Fourel et al., 1994) . P-labeled Fgf8 cDNA probe as described previously (Shackleford and Varmus, 1987) . RNAs from normal mammary tissue of breeding mice, M, and a tumor known to be positive for Fgf8 expression, C, are indicated. The upper panels show the hybridization signals from the membranes after Northern transfer, and the lower panels display ethidium bromide stained RNA gels before blotting. Numbers to the right of the panels indicate the positions of RNA size markers in kilobases P-labeled probes stated below as described previously . (a) The blots were ®rst hybridized with an MMTV gag probe. In addition to the endogenous MMTV proviruses, exogenous proviruses are detected as tumor-speci®c fragments of unique size, indicating independent clonal or quasi-clonal populations of infected cells. (b) Subsequently, the blots were stripped of the gag probe and hybridized with a mixture of Fgf8 probes. An Fgf8a cDNA probe was used in combination with probes called XP1200 (left blot) or BB2.4 (right blot) to detect regions surrounding the Fgf8 gene of *30 kb or *36 kb, respectively. The XP1200 probe detects a DNA fragment of *6 kb containing a Nub1 pseudogene (MacArthur et al., 1995) , now called Npm3-ps1 (MacArthur and Shackleford, 1997) , in addition to a *21 kb fragment at the Fgf8 locus. Only two tumors (35 and 44) showed rearrangements in the Fgf8 locus despite the fact that Fgf8 is transcriptionally activated in all of the tumors. Arrowheads indicate fragments that hybridize to both gag and Fgf8 probes. Numbers to the right of the blots indicate the positions of DNA size markers in kilobases , 1988) , an Fgf4 clone called HH1 (Peters et al., 1989a) , and Wnt1 cDNA clone #26 (Fung et al., 1985) genic mice, such events have not been reported in infected nontransgenic mice. We therefore examined this issue by Northern analysis using tumor RNAs from MMTV-infected nontransgenic littermates of the Wnt1 transgenics and from MMTV-infected BALB/c mice. Blots were hybridized with a probe for Fgf8 (Figures 1b and 3) as well as probes for Fgf3, Fgf4 and Wnt1 to allow a comparison to the transgenic results above.
Fgf8 was found to be activated in 11% (7/65) of these tumors, with similar frequencies in both subgroups: 9% (3/32) of nontransgenic littermates and 12% (4/33) of BALB/c tumors (Figure 3) . Activations of Fgf3, Fgf4 and Wnt1 were seen in 72% (23/32), 3% (1/32) and 31% (10/32) of the tumors from the nontransgenic littermates compared to 88% (29/33), 6% (2/32) and 59% (19/32) in the BALB/c group, respectively. The sum of the percentages for each group is greater than 100%, since some tumors showed activations of more than one gene. The disparity in Wnt1 activation frequencies between the two nontransgenic groups (Chi square test; P50.001) is most likely due to the dierences in the genetic backgrounds (Marchetti et al., 1991) . Proviral insertions were not detected in the *36 kb region containing the Fgf8 gene in tumors from the nontransgenic littermate group that showed Fgf8 expression (data not shown), suggesting long distance activation by MMTV in these tumors.
In summary, there is an apparent selection for Fgf8 activations in MMTV-infected Wnt1 transgenic mice. Our results show that the activation of Fgf8 was signi®cantly more frequent, 4.5-fold higher, in tumors from transgenic mice (50%) than from both groups of nontransgenic mice (littermates and BALB/c; average 11%), demonstrating that Wnt1 and Fgf8 are powerful collaborators in mammary carcinogenesis. In contrast, the activation frequency of Fgf3 in tumors from transgenic mice (44%) was approximately one-half that of both groups of nontransgenic mice (average 80%). The dierences in activation frequencies between the transgenic and nontransgenic tumor groups for both Fgf8 and Fgf3 were statistically signi®cant ( Figure  3 ). Moreover, a striking dierence is apparent in the ratio of Fgf8 to Fgf3 activations in the transgenic group (50%:44%) compared to the ratio in the combined nontransgenic group (11%:80%). These results indicate that there is a strong preference for the activation of Fgf8 when Wnt1 expression is present. The selection for Fgf8 activations apparently requires the preexisting expression of Wnt1 in cells, since there are only a few tumors in the nontransgenic group with double activations of both Fgf8 and Wnt1. It is possible that the selection of Fgf8 activations in Wnt1-expressing cells is uncovering an important cooperative event that occurs normally between these two pathways, especially considering the mounting evidence that FGFs and Wnts collaborate in normal development (Christian et al., 1992; Crossley and Martin, 1995; Parr and McMahon, 1995; Yang and Niswander, 1995; Crossley et al., 1996) .
At least two possibilities may be proposed to explain the observed dierences in activation frequencies between the transgenic versus normal tumor groups, in particular the elevated frequency of Fgf8 activations in Wnt1 transgenic animals. One might propose that the absence of Wnt1 as an activation target in the Wnt1 transgenics (since Wnt1 is already activated in these mice) would result in an increase in the activation frequencies of other genes in these animals. However, since we observe fewer, not more, Fgf3 activations in transgenic versus nontransgenic tumors, the explanation is not likely to be as simple as target competition.
More likely, this system may be detecting dierences in the signaling pathways of the two ligands, FGF3 and FGF8. For example, it is possible that Wnt1 stimulation modulates the expression or activity of one or more components in the FGF8 signaling pathway, such as an FGF8 receptor or a protein(s) farther downstream in the pathway, resulting in enhanced signal transduction. Consistent with this hypothesis is the observation that FGF3 and FGF8 preferentially utilize dierent FGF receptors (Ornitz et al., 1996) . Further investigation will be necessary to determine the exact mechanism of the increased oncogenicity of FGF8 in the presence of Wnt1.
In conclusion, the proviral activation frequency of Fgf8, but not Fgf3 or Fgf4, in mammary tumors increased dramatically in the context of Wnt1 transgene expression. Cells expressing Wnt1 appear to be particularly sensitized to signaling by FGF8, suggesting that Wnt1 signaling may modulate some aspects of the FGF8 signal transduction pathway.
